Last Updated: 19 Sep 2024
Executive Summary
Renalytix AI (RNLX) is a clinical-stage diagnostics company focused on developing artificial intelligence (AI)-enabled in vitro diagnostic (IVD) solutions for kidney diseases. The company's primary product, KidneyIntelX, is a blood-based test that can predict the risk of acute kidney injury (AKI) and chronic kidney disease (CKD).
Company Overview
Renalytix AI was founded in 2018 and is headquartered in Cardiff, UK. The company has operations in the US, Europe, and Asia. Renalytix AI's mission is to improve the lives of patients with kidney diseases by providing accurate and timely diagnostic information.
Fundamental Analysis
Revenue: Renalytix AI's revenue for the latest quarter (ending March 31, 2024) was $2.22 million, a decrease of 0.26% year-over-year.
Gross Profit: Gross profit for the latest quarter was $0.72 million, a decrease of 11.47% year-over-year.
Net Loss: Net loss for the latest quarter was $33.07 million, an increase of 0.00% year-over-year.
EPS: Diluted EPS for the latest quarter was -$0.76, a decrease of 0.00% year-over-year.
Book Value: Book value per share is -$0.093.
Price-to-Sales Ratio: The price-to-sales ratio is 10.86.
Price-to-Book Ratio: The price-to-book ratio is 18.77.
Technical Analysis
52-Week High: $2.29
52-Week Low: $0.22
50-Day Moving Average: $0.335
200-Day Moving Average: $0.528
Beta: 2.104
Short Term Outlook
The technical analysis suggests that RNLX is in a downtrend. The stock price is below both the 50-day and 200-day moving averages. The beta of 2.104 indicates that the stock is more volatile than the market as a whole.
Long Term Outlook
The long-term outlook for RNLX is uncertain. The company is still in the early stages of commercializing its products. If Renalytix AI can successfully execute its growth strategy, it could become a major player in the kidney disease diagnostics market. However, the company faces significant competition from established players such as Abbott Laboratories and Siemens Healthineers.
Analyst Recommendations
Two analysts have a Strong Buy rating on RNLX, while one analyst has a Buy rating. The average analyst target price is $2.50.
